Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

ANB032 was well tolerated across all doses with no safety signals observed; AD trial and all further investment in ANB032 will be discontinued; Anticipate top-line Phase 2b data i ...

Christopher Wray Will Step Down as F.B.I. Director President-elect Trump had already signaled his intention to replace Mr. Wray with a longtime loyalist, Kash Patel. U.S. Colleges Warn Foreign ...

December 12, 2024 • In 2012, Karam Shaar had to leave his home country of Syria due to the civil war. But he still wanted to make a difference. Through his economic analysis, he uncovered ...

New Zealand Rugby have revealed the nation’s Under 18s squads for the Global Youth Sevens in Auckland this weekend. Seven Wallabies have been ranked among the sport’s elite in the RugbyPass Top 100 ...

US Bankers Are Cautious Towards Cryptos Despite Upcoming Pro-Crypto Administration ...